Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deucravacitinib in Moderate-to-Severe Plaque Psoriasis (POETYK PSO-2)
NCT03611751Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2018
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 16
01
Overview
A Phase 3 trial of deucravacitinib in plaque psoriasis, sponsored by Bristol Myers Squibb. Started Jul 2018; status: completed.
02
Drugs
deucravacitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03611751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03611751.